Annals of Oncology Advance Access originally published online on July 27, 2006
Annals of Oncology 2006 17(10):1517-1522; doi:10.1093/annonc/mdl159
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 European Society for Medical Oncology
breast cancer |
Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome
1 Department of Biochemistry and Molecular Biology, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, China
2 Department of Pathology, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, China
3 People Hospital of Henan Province, Zhengzhou, HeNan, China
4 Breast Center, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, China
*Correspondence to: Dr Y. Xie or Dr C. Shou, Peking University School of Oncology, Beijing Cancer Hospital and Institute, 100036 Beijing, P. R. China; Phone: +86-10-88196362 or +86-10-88196766; E-mail: zlxyt2{at}bjmu.edu.cn or cshou{at}vip.sina.com
Background: Increasing evidence has suggested that phosphatase of regenerating liver-3 (PRL-3) plays an important role in cancer cell migration, invasion and metastasis. However, the correlation between the PRL-3 expression and clinical outcome in breast cancer has not been investigated.
Patients and methods: Using a PRL-3-specific monoclonal antibody 3B6, PRL-3 expression was assessed by immunohistochemistry in tumor tissues from 382 breast cancer patients with a median follow-up of 65 months.
Results: We found that 34.8% patients expressed a high level of PRL-3 protein in their tumors. Patients with a high level of PRL-3 in the tumor had a worse disease-specific survival (DSS) rate than those with a low level of PRL-3 (74.0% versus 84.9%, P = 0.011), and PRL-3 remained an independent prognostic marker for DSS (HR 1.8, 95% CI 1.1–2.9, P = 0.019) in multivariate analysis. More importantly, in 219 node-negative patients, PRL-3 showed a significant correlation with DSS in univariate analysis (P = 0.014) and retained a borderline significance (HR 2.65, 95% CI 0.92–7.64, P = 0.071) in multivariate analysis.
Conclusions: Our results suggest that PRL-3 may serve as an unfavorable prognostic marker in breast cancer, especially for patients with node-negative diseases. Thus, our findings may provide useful information for individualized therapy in the clinical setting.
Key words: breast cancer, PRL-3, prognosis
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  U.-M. Fagerli, R. U. Holt, T. Holien, T. K. Vaatsveen, F. Zhan, K. W. Egeberg, B. Barlogie, A. Waage, H. Aarset, H. Y. Dai, et al. Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells Blood, January 15, 2008; 111(2): 806 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Stephens, H. Han, G. Hostetter, M. J. Demeure, and D. D. Von Hoff Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells Mol. Cancer Ther., January 1, 2008; 7(1): 202 - 210. [Abstract] [Full Text] [PDF]
|
|